JP2011225578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011225578A5 JP2011225578A5 JP2011121539A JP2011121539A JP2011225578A5 JP 2011225578 A5 JP2011225578 A5 JP 2011225578A5 JP 2011121539 A JP2011121539 A JP 2011121539A JP 2011121539 A JP2011121539 A JP 2011121539A JP 2011225578 A5 JP2011225578 A5 JP 2011225578A5
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- vlp
- group
- vaccine formulation
- nacl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701806 Human papillomavirus Species 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- -1 fatty acid ester Chemical class 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 229920004929 Triton X-114 Polymers 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000005215 alkyl ethers Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11872399P | 1999-02-05 | 1999-02-05 | |
| US60/118,723 | 1999-02-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596960A Division JP4841726B2 (ja) | 1999-02-05 | 2000-02-01 | ヒトパピローマウイルスワクチン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011225578A JP2011225578A (ja) | 2011-11-10 |
| JP2011225578A5 true JP2011225578A5 (enExample) | 2012-08-30 |
Family
ID=22380362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596960A Expired - Lifetime JP4841726B2 (ja) | 1999-02-05 | 2000-02-01 | ヒトパピローマウイルスワクチン製剤 |
| JP2011121539A Withdrawn JP2011225578A (ja) | 1999-02-05 | 2011-05-31 | ヒトパピローマウイルスワクチン製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596960A Expired - Lifetime JP4841726B2 (ja) | 1999-02-05 | 2000-02-01 | ヒトパピローマウイルスワクチン製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6251678B1 (enExample) |
| EP (1) | EP1150712B1 (enExample) |
| JP (2) | JP4841726B2 (enExample) |
| KR (1) | KR20010093290A (enExample) |
| AR (1) | AR022510A1 (enExample) |
| AT (1) | ATE413188T1 (enExample) |
| AU (1) | AU764138B2 (enExample) |
| CA (1) | CA2361837C (enExample) |
| CY (1) | CY1108702T1 (enExample) |
| DE (1) | DE60040727D1 (enExample) |
| DK (1) | DK1150712T3 (enExample) |
| ES (1) | ES2313881T3 (enExample) |
| PT (1) | PT1150712E (enExample) |
| SI (1) | SI1150712T1 (enExample) |
| WO (1) | WO2000045841A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA982950B (en) * | 1997-04-08 | 1998-10-19 | Merck & Co Inc | Stabilized human papillomavirus formulations |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| CA2799545A1 (en) * | 2000-03-07 | 2001-09-13 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| CA2327950A1 (en) * | 2000-12-08 | 2002-06-08 | Groupe Minutia Inc. | Grain refining agent for cast aluminum or magnesium products |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| DE10137102A1 (de) | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| BR0306925A (pt) * | 2002-01-18 | 2004-11-09 | Schering Ag | Formulações estabilizadas de adenovìrus |
| WO2003068933A2 (en) * | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| ATE503492T1 (de) * | 2002-12-20 | 2011-04-15 | Glaxosmithkline Biolog Sa | Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| JP2007001865A (ja) * | 2003-09-16 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤 |
| BRPI0417938A (pt) | 2003-12-30 | 2007-04-17 | Wyeth Corp | formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada |
| US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| RU2417793C2 (ru) * | 2004-10-05 | 2011-05-10 | Цитос Биотехнологи Аг | Конъюгаты впч-антиген и их применение в качестве вакцин |
| WO2006037787A2 (en) * | 2004-10-05 | 2006-04-13 | Cytos Biotechnology Ag | Vlp-antigen conjugates and their uses as vaccines |
| JP4182074B2 (ja) * | 2005-03-03 | 2008-11-19 | ファナック株式会社 | ハンド及びハンドリングロボット |
| CN101171033A (zh) * | 2005-03-04 | 2008-04-30 | 戴纳瓦克斯技术公司 | 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定 |
| AU2006236905B2 (en) | 2005-04-15 | 2010-06-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| HUE032422T2 (en) | 2006-09-29 | 2017-09-28 | Takeda Vaccines Inc | Norovirus vaccine preparations |
| WO2008058035A1 (en) * | 2006-11-03 | 2008-05-15 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
| EP2129394B1 (en) * | 2007-03-09 | 2012-06-20 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| EP2258380B1 (en) * | 2008-03-31 | 2013-03-13 | Morinaga Milk Industry Co., Ltd. | Nucleic acid for imparting heat resistance to lactoferrin |
| WO2011079260A2 (en) * | 2009-12-23 | 2011-06-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Stabilized virus like particles having enhanced mucosal immunogenicity |
| PL3831406T3 (pl) | 2010-08-23 | 2024-09-09 | Wyeth Llc | Stabilne preparaty antygenów rLP2086 Neisseria meningitidis |
| RU2546873C2 (ru) | 2010-09-10 | 2015-04-10 | УАЙТ ЭлЭлСи | Нелипидизированные варианты антигенов neisseria meningitidis orf2086 |
| WO2012038801A1 (en) | 2010-09-21 | 2012-03-29 | National Institute Of Immunology | A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
| AU2012272788B2 (en) * | 2011-06-24 | 2016-10-20 | Merck Sharp & Dohme Llc | HPV vaccine formulations comprising aluminum adjuvant and methods of producing same |
| EA029470B1 (ru) | 2011-07-11 | 2018-03-30 | Такеда Вэксинс, Инк. | Способ стимулирования формирования защитного иммунитета против норовируса |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| ES2765880T3 (es) | 2012-01-09 | 2020-06-11 | Sanofi Pasteur Biologics Llc | Purificación del virus del herpes |
| MY167723A (en) | 2012-03-09 | 2018-09-21 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| CA2873775C (en) | 2012-05-21 | 2021-04-20 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
| KR101705268B1 (ko) | 2012-06-20 | 2017-02-09 | 고쿠리츠다이가쿠호징 도쿄다이가쿠 | 점막 면역 부활화제 및 hpv 감염증 치료용 경구 의약 조성물 |
| JOP20130186B1 (ar) * | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| TR201809679T4 (tr) * | 2012-12-28 | 2018-07-23 | Cellestis Ltd | Hücre aracılı bir immün yanıt tahlili. |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| US9254332B2 (en) | 2013-03-15 | 2016-02-09 | Arecor Limited | Stable aqueous formulations of adenovirus vectors |
| EP4098276A1 (en) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| US20170212116A1 (en) | 2014-01-31 | 2017-07-27 | Ulisse Biomed Srl | Biosensors for the detection of infection and associated maladies |
| CN104479892A (zh) * | 2014-11-06 | 2015-04-01 | 王越 | 一种具有植物杀菌功能洗衣液的制备方法 |
| US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2017173371A1 (en) | 2016-04-01 | 2017-10-05 | Colorado State University Research Foundation | Compositions and methods for enhanced innate immunity |
| US12508279B2 (en) | 2016-04-01 | 2025-12-30 | Colorado State University Research Foundation | Compositions and methods for enhancing innate immunity in a subject for treatment of infections and cancer and other acute and chronic conditions of the eye |
| PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CA3079828A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Stable formulations of cytomegalovirus |
| CN112439059B (zh) * | 2019-09-02 | 2022-02-08 | 怡道生物科技(苏州)有限公司 | 重组人乳头瘤病毒疫苗组合物及其用途 |
| WO2021059181A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| JP2026000483A (ja) * | 2022-11-22 | 2026-01-06 | 一般財団法人阪大微生物病研究会 | 安定化されたｖｌｐワクチン |
| WO2025216920A1 (en) * | 2024-04-08 | 2025-10-16 | The Government Of The United States, As Represented By The Secretary Of The Army | Freezable aqueous aluminum salt adjuvants |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320782D0 (en) * | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US5569468A (en) * | 1994-02-17 | 1996-10-29 | Modi; Pankaj | Vaccine delivery system for immunization, using biodegradable polymer microspheres |
| BR9507657A (pt) * | 1994-05-16 | 1997-09-09 | Merck & Co Inc | Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte |
| AUPM566794A0 (en) | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
| AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| IL117459A (en) | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| IL117591A0 (en) | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| JP4653262B2 (ja) * | 1996-09-26 | 2011-03-16 | メルク・シャープ・エンド・ドーム・コーポレイション | ロタウイルスワクチン製剤類 |
| JP2002515056A (ja) * | 1997-02-06 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ワクチン用チメロサールフリー保存剤 |
| SK138199A3 (en) * | 1997-04-08 | 2000-06-12 | Merck & Co Inc | Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus |
-
2000
- 2000-02-01 SI SI200031009T patent/SI1150712T1/sl unknown
- 2000-02-01 DE DE60040727T patent/DE60040727D1/de not_active Expired - Lifetime
- 2000-02-01 DK DK00905886T patent/DK1150712T3/da active
- 2000-02-01 AT AT00905886T patent/ATE413188T1/de active
- 2000-02-01 KR KR1020017009504A patent/KR20010093290A/ko not_active Withdrawn
- 2000-02-01 AU AU27492/00A patent/AU764138B2/en not_active Expired
- 2000-02-01 PT PT00905886T patent/PT1150712E/pt unknown
- 2000-02-01 WO PCT/US2000/002463 patent/WO2000045841A2/en not_active Ceased
- 2000-02-01 JP JP2000596960A patent/JP4841726B2/ja not_active Expired - Lifetime
- 2000-02-01 CA CA2361837A patent/CA2361837C/en not_active Expired - Lifetime
- 2000-02-01 EP EP00905886A patent/EP1150712B1/en not_active Expired - Lifetime
- 2000-02-01 ES ES00905886T patent/ES2313881T3/es not_active Expired - Lifetime
- 2000-02-02 US US09/496,812 patent/US6251678B1/en not_active Expired - Lifetime
- 2000-02-04 AR ARP000100495A patent/AR022510A1/es unknown
-
2009
- 2009-01-15 CY CY20091100051T patent/CY1108702T1/el unknown
-
2011
- 2011-05-31 JP JP2011121539A patent/JP2011225578A/ja not_active Withdrawn